Fosinopril

CHEMBL3039598 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
563.7 g/mol
LogP
6.2
Phase
4

This ACE inhibitor lowers blood pressure by blocking the enzyme that produces angiotensin II, a potent blood vessel constrictor, allowing blood vessels to relax. It is used to treat high blood pressure and heart failure, and may offer protective benefits for the kidneys.

분자량

563.7000 g/mol

LogP

6.20

TPSA

110.00 Ų

리핀스키 5의 법칙

불통과

치료 영역

작용 기전

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C

InChI

InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30+,39-/m1/s1

Molecular Formula

C30H46NO7P

HBD / HBA

1 / 7

회전 가능 결합

15

무거운 원자

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This ACE inhibitor lowers blood pressure by blocking the enzyme that produces angiotensin II, a potent blood vessel constrictor, allowing blood vessels to relax. It is used to treat high blood pressure and heart failure, and may offer protective benefits for the kidneys.

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Yes, Fosinopril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3039598. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9601226. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.